Background Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality.
Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...
We believe that pharmacologic innovation is needed in treating patients with cardiogenic shock,” said Dr. Steve Simonson, CMO and SVP of Windtree. “Currently available drugs can have unwanted ...
The company’s lead development program, istaroxime, is being developed for the treatment of acute decompensated heart failure (ADHF) and cardiogenic shock; Aerosurf, a lucinactant for inhalation, and ...
Two heart pump systems were approved for the treatment of acute decompensated HF and cardiogenic shock in certain pediatric patients. Real-world data are needed to support on-label use.
Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.
Treatment of cardiogenic shock is aimed at correcting the primary etiology and hemodynamic support with cardiac inotropes such as dobutamine or milrinone.